FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293331135> ?p ?o ?g. }

• W4293331135 endingPage "1524" @default.
• W4293331135 startingPage "1517" @default.
• W4293331135 abstract "The binding of IL-33 to its receptor ST2 (alias of IL1RL1) leads to the release of inflammatory mediators and may play a role in the pathogenesis of atopic dermatitis. Astegolimab is a fully human, IgG2 mAb that binds to ST2 and inhibits IL-33 signaling.This study sought to assess the efficacy, safety, and pharmacokinetics of astegolimab in patients with atopic dermatitis.This was a randomized, placebo-controlled, phase 2 study in which adults with chronic atopic dermatitis were randomized 1:1 to receive astegolimab 490 mg every 4 weeks or placebo, for 16 weeks. The primary outcome was the percentage of change from baseline to week 16 of the Eczema Area and Severity Index score.A total of 65 patients were enrolled in the study (placebo, n = 32; astegolimab, n = 33). The adjusted mean percentage of change from baseline to week 16 in the Eczema Area and Severity Index score was -51.47% for astegolimab compared with -58.24% for placebo, with a nonsignificant treatment difference of 6.77% (95% CI: -16.57-30.11; P = .5624). No differences were observed between treatment groups for secondary efficacy outcomes and in exploratory biomarkers (blood eosinophils, serum IL-5, serum CCL13). With the use of loading dose, pharmacokinetic exposure was sufficient from week 1. Astegolimab was well-tolerated, with a safety profile consistent with that observed in previous clinical trials.In patients with atopic dermatitis, astegolimab did not show a significant difference compared to placebo for the primary or secondary outcomes." @default.
• W4293331135 created "2022-08-27" @default.
• W4293331135 creator A5008679193 @default.
• W4293331135 creator A5015289452 @default.
• W4293331135 creator A5018952212 @default.
• W4293331135 creator A5048765625 @default.
• W4293331135 creator A5058508137 @default.
• W4293331135 creator A5068431501 @default.
• W4293331135 creator A5069429997 @default.
• W4293331135 creator A5082065479 @default.
• W4293331135 creator A5091156366 @default.
• W4293331135 creator A5091297501 @default.
• W4293331135 date "2022-12-01" @default.
• W4293331135 modified "2023-10-14" @default.
• W4293331135 title "Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis" @default.
• W4293331135 cites W1783260908 @default.
• W4293331135 cites W1988035869 @default.
• W4293331135 cites W2012434022 @default.
• W4293331135 cites W2023110519 @default.
• W4293331135 cites W2073856262 @default.
• W4293331135 cites W2110816580 @default.
• W4293331135 cites W2116889630 @default.
• W4293331135 cites W2117359358 @default.
• W4293331135 cites W2117983771 @default.
• W4293331135 cites W2122674341 @default.
• W4293331135 cites W2130509509 @default.
• W4293331135 cites W2154230203 @default.
• W4293331135 cites W2258263985 @default.
• W4293331135 cites W2270215994 @default.
• W4293331135 cites W2306524933 @default.
• W4293331135 cites W2521483984 @default.
• W4293331135 cites W2547989912 @default.
• W4293331135 cites W2549478702 @default.
• W4293331135 cites W2593244680 @default.
• W4293331135 cites W2609744794 @default.
• W4293331135 cites W2860751079 @default.
• W4293331135 cites W2951542229 @default.
• W4293331135 cites W2969959484 @default.
• W4293331135 cites W2979421310 @default.
• W4293331135 cites W3152867209 @default.
• W4293331135 cites W4211026773 @default.
• W4293331135 cites W4230355606 @default.
• W4293331135 doi "https://doi.org/10.1016/j.jaci.2022.08.015" @default.
• W4293331135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36041655" @default.
• W4293331135 hasPublicationYear "2022" @default.
• W4293331135 type Work @default.
• W4293331135 citedByCount "11" @default.
• W4293331135 countsByYear W42933311352022 @default.
• W4293331135 countsByYear W42933311352023 @default.
• W4293331135 crossrefType "journal-article" @default.
• W4293331135 hasAuthorship W4293331135A5008679193 @default.
• W4293331135 hasAuthorship W4293331135A5015289452 @default.
• W4293331135 hasAuthorship W4293331135A5018952212 @default.
• W4293331135 hasAuthorship W4293331135A5048765625 @default.
• W4293331135 hasAuthorship W4293331135A5058508137 @default.
• W4293331135 hasAuthorship W4293331135A5068431501 @default.
• W4293331135 hasAuthorship W4293331135A5069429997 @default.
• W4293331135 hasAuthorship W4293331135A5082065479 @default.
• W4293331135 hasAuthorship W4293331135A5091156366 @default.
• W4293331135 hasAuthorship W4293331135A5091297501 @default.
• W4293331135 hasConcept C112705442 @default.
• W4293331135 hasConcept C126322002 @default.
• W4293331135 hasConcept C142724271 @default.
• W4293331135 hasConcept C168563851 @default.
• W4293331135 hasConcept C203014093 @default.
• W4293331135 hasConcept C204787440 @default.
• W4293331135 hasConcept C27081682 @default.
• W4293331135 hasConcept C2776173921 @default.
• W4293331135 hasConcept C2778329239 @default.
• W4293331135 hasConcept C2779134260 @default.
• W4293331135 hasConcept C2780501606 @default.
• W4293331135 hasConcept C2780699399 @default.
• W4293331135 hasConcept C535046627 @default.
• W4293331135 hasConcept C71924100 @default.
• W4293331135 hasConcept C90924648 @default.
• W4293331135 hasConceptScore W4293331135C112705442 @default.
• W4293331135 hasConceptScore W4293331135C126322002 @default.
• W4293331135 hasConceptScore W4293331135C142724271 @default.
• W4293331135 hasConceptScore W4293331135C168563851 @default.
• W4293331135 hasConceptScore W4293331135C203014093 @default.
• W4293331135 hasConceptScore W4293331135C204787440 @default.
• W4293331135 hasConceptScore W4293331135C27081682 @default.
• W4293331135 hasConceptScore W4293331135C2776173921 @default.
• W4293331135 hasConceptScore W4293331135C2778329239 @default.
• W4293331135 hasConceptScore W4293331135C2779134260 @default.
• W4293331135 hasConceptScore W4293331135C2780501606 @default.
• W4293331135 hasConceptScore W4293331135C2780699399 @default.
• W4293331135 hasConceptScore W4293331135C535046627 @default.
• W4293331135 hasConceptScore W4293331135C71924100 @default.
• W4293331135 hasConceptScore W4293331135C90924648 @default.
• W4293331135 hasIssue "6" @default.
• W4293331135 hasLocation W42933311351 @default.
• W4293331135 hasLocation W42933311352 @default.
• W4293331135 hasOpenAccess W4293331135 @default.
• W4293331135 hasPrimaryLocation W42933311351 @default.
• W4293331135 hasRelatedWork W2003620798 @default.
• W4293331135 hasRelatedWork W2748617188 @default.
• W4293331135 hasRelatedWork W2766528424 @default.

• next